Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.
Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Sosenko JM, et al. Among authors: herold kc. Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10. Diabetes Care. 2015. PMID: 25758770 Free PMC article.
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1.
Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group. Sosenko JM, et al. Among authors: herold kc. Diabetes Care. 2007 Jan;30(1):38-42. doi: 10.2337/dc06-1615. Diabetes Care. 2007. PMID: 17192330
Prevention of type 1 diabetes: the time has come.
Sherr J, Sosenko J, Skyler JS, Herold KC. Sherr J, et al. Among authors: herold kc. Nat Clin Pract Endocrinol Metab. 2008 Jun;4(6):334-43. doi: 10.1038/ncpendmet0832. Epub 2008 Apr 29. Nat Clin Pract Endocrinol Metab. 2008. PMID: 18446141 Review.
Beta-cell mass and type 1 diabetes: going, going, gone?
Akirav E, Kushner JA, Herold KC. Akirav E, et al. Among authors: herold kc. Diabetes. 2008 Nov;57(11):2883-8. doi: 10.2337/db07-1817. Diabetes. 2008. PMID: 18971435 Free PMC article. Review.
Anti-CD3 mAbs for treatment of type 1 diabetes.
Kaufman A, Herold KC. Kaufman A, et al. Among authors: herold kc. Diabetes Metab Res Rev. 2009 May;25(4):302-6. doi: 10.1002/dmrr.933. Diabetes Metab Res Rev. 2009. PMID: 19319985 Review.
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group. Herold KC, et al. Clin Immunol. 2009 Aug;132(2):166-73. doi: 10.1016/j.clim.2009.04.007. Epub 2009 May 14. Clin Immunol. 2009. PMID: 19443276 Free PMC article. Clinical Trial.
Challenges in developing endpoints for type 1 diabetes intervention studies.
Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RD, Skyler JS, Palmer JP; D-Cure Workshop. Cernea S, et al. Among authors: herold kc. Diabetes Metab Res Rev. 2009 Nov;25(8):694-704. doi: 10.1002/dmrr.1002. Diabetes Metab Res Rev. 2009. PMID: 19771545 Review.
260 results